Proteins key to understanding DR

Article

Diabetes-induced changes to 37 separate proteins of the vitreous may be the key to understanding the mechanisms of diabetic retinopathy (DR), according to a study to be published in the June issue of the Journal of Proteome Research.

Diabetes-induced changes to 37 separate proteins of the vitreous may be the key to understanding the mechanisms of diabetic retinopathy (DR), according to a study to be published in the June issue of the Journal of Proteome Research.

Edward P. Feener, PhD of Harvard Medical School, US and colleagues performed a proteomic analysis and compared vitreous samples from 17 subjects, comprising those without diabetes (NDM), those with diabetes but without DR (noDR), and those with DR.

The team found that, of the 252 proteins identified in the vitreous, 56 were found to be in statistically significantly different levels in noDR and DR subjects compared with NDM subjects. This included 32 proteins that were increased and 10 proteins that were decreased in DR subjects compared with NDM subjects. Of the 30 proteins associated with the kallikrein-kinin, coagulation, and complement systems within the vitreous, five were increased in DR subjects compared with NDM subjects. Factor XII was present only in the vitreous of DR subjects.

This new understanding of the biochemical changes found in the eyes of DR patients could, the team believes, further understanding of DR mechanisms of action, thereby leading to new treatment options.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.